AbbVie Reports Promising Early Results for Experimental Obesity Drug ABBV-295

AbbVie has reported positive topline results from a Phase 1 clinical study of its investigational obesity treatment ABBV-295, showing meaningful weight reduction and a favorable safety profile.

The therapy represents a new treatment approach for chronic weight management, operating through a non-incretin mechanism distinct from popular obesity drugs targeting GLP-1 and GIP receptors.

Significant Weight Loss Observed in Early Trial

The results come from the multiple ascending dose (MAD) portion of a Phase 1 study evaluating the drug’s safety, tolerability, pharmacokinetics, and pharmacodynamics.

Participants receiving ABBV-295 experienced dose-dependent reductions in body weight over a 12–13 week treatment period.

Key findings include:

• 7.75% to 9.79% weight reduction at week 12 in weekly dosing groups
• 7.86% to 9.73% weight reduction at week 13 in every-other-week and monthly dosing groups
• Placebo groups showed only ~0.25% weight change

The study enrolled adults with an average body mass index below 30 kg/m², with 88.3% of participants being male.

Favorable Safety and Tolerability Profile

ABBV-295 was generally well tolerated across all tested doses (2–14 mg).

Notable safety findings:

• No serious adverse events reported
• Most side effects were mild gastrointestinal symptoms
• GI symptoms mainly occurred during the first six weeks of treatment

These results suggest the drug could support long-term adherence, an important factor in obesity therapy.

A Different Mechanism from GLP-1 Drugs

Unlike widely used obesity therapies that target incretin pathways, ABBV-295 is a long-acting amylin analog.

Amylin works by:

• Sending satiety signals to the brain
• Reducing food intake
• Slowing gastric emptying

By activating amylin and calcitonin receptors, the drug aims to suppress appetite through a different biological pathway. This could potentially position ABBV-295 as a differentiated alternative to incretin-based treatments.

Company Perspective

Primal Kaur, Senior Vice President of Global Development at AbbVie, emphasized the need for more effective obesity therapies.

“Obesity is a complex chronic disease, and there remains a critical need for treatments that combine efficacy with tolerability and support long-term adherence.”

She added that the early findings reinforce the potential of ABBV-295 as a novel therapeutic option for people living with obesity.

Next Steps for Development

The Phase 1 trial—registered as NCT06144684—included 76 participants and evaluated both single ascending dose and multiple ascending dose cohorts.

Full data from the study will be presented at a future scientific conference, while the company continues clinical development of the therapy.

ABBV-295 remains investigational and has not yet been approved by any regulatory authority worldwide.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!